Embecta Corp.

NASDAQ:EMBC

Drug Manufacturers - Specialty & Generic

Healthcare
$6.09 +0.65%

+$0.02 today

Market cap
$345.06M
Beta
0.81
P/E (TTM)
1.6
EPS (TTM)
$1.92
Dividend yield
14.79%
52W Low $2.77High $15.55

Volume 0.72M

Average 1.95M

EMBC Deferred Revenue

Payments received for goods or services the company will deliver within the next year.

Embecta Corp.NASDAQ: EMBC

Deferred Revenue · Q2 FY2026 · quarter ended Mar 2026

Deferred revenue remains negative

Q2 FY2026 deferred revenue was $0, compared with $0 a year earlier.

Context

  • Deferred revenue amounted to 0.0% of total assets at the end of Q2 FY2026, unchanged from a year earlier.
  • Deferred revenue increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearSep 2025
$0— YoY
Year agoMar 2025
$0— since
Deferred Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Deferred Revenue history

USD · from the balance sheet

Latest · FY2025
0 USD
Year-over-year change
—

Deferred Revenue vs competitors

How EMBC compares with its peers on the latest reported figures

  • EMBC's Mar 2026 deferred revenue of $0 is the 8th highest of the 11 companies compared; the peer median is $2.79M.
  • Deferred revenue amounts to 0.0% of total assets for EMBC, versus a peer median of 0.8%.
EMBC Competitors Peer median
Deferred Revenue for EMBC and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
EBSEmergent BioSolutions Inc.Mar 2026$12.2M ——0.9%
SIGASIGA Technologies, Inc.Mar 2026$8.88M -14.0%-1.0%4.0%
PRMEPrime Medicine, Inc.Mar 2026$7.32M -10.9%—2.5%
CDNACareDx, IncJun 2026$5.55M -6.8%-4.5%1.0%
PSNLPersonalis, Inc.Mar 2026$4.17M +112.2%+6.5%1.3%
EVHEvolent Health, Inc.Mar 2026$1.42M -71.8%-40.7%0.1%
AQSTAquestive Therapeutics, Inc.Mar 2026$1.09M +4.2%-10.3%0.8%
EMBCEmbecta Corp.Mar 2026$0 ——0.0%
VIRVir Biotechnology, Inc.Mar 2026$0 -100.0%—0.0%
MRVIMaravai LifeSciences Holdings, Inc.Jun 2026$0 -100.0%—0.0%
MYGNMyriad Genetics, Inc.Mar 2026$0 ——0.0%
Peer median (excluding EMBC) $2.79M-12.4%-4.5%0.8%

Competitors are the stored peer set for EMBC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Sep 2021
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Cash & Equivalents0330.9M326.3M267.5M225.5M
Short-term Investments00000
Net Receivables150.6M23.4M17.9M248M148.9M
Inventory118M122.8M152.1M171.5M178.6M
Other Current Assets200K109.7M142.4M74M3.1M
Total Current Assets292M664.7M749.1M761M631.4M
Property, Plant & Equipment (Net)451M301.6M323.2M290.4M48.5M
Goodwill16M15.7M15.6M15.6M15.4M
Intangible Assets18M8.9M9.1M8.1M7M
Long-term Investments(11.4M)(95.5M)000
Tax Assets11.4M95.5M0020.2M
Other Non-current Assets11M95.5M117.4M210.2M368.4M
Total Non-current Assets496M421.7M465.3M524.3M459.5M
Total Assets788M1.09B1.21B1.29B1.09B
Account Payables54.2M41.4M53.5M91M74.2M
Short-term Debt1M9.5M9.5M9.5M12.9M
Tax Payables027.2M33.6M26.7M0
Deferred Revenue0033.6M00
Other Current Liabilities0198M33.6M0115.2M
Total Current Liabilities164M301M353.5M374M261.5M
Long-term Debt01.6B1.59B1.57B1.39B
Deferred Tax Liabilities046.1M011.9M62.6M
Deferred Revenue (Non-current)0(46.1M)000
Other Non-current Liabilities26.7M41.8M57.2M42.2M63.2M
Total Non-current Liabilities29.7M1.68B1.68B1.65B1.48B
Total Liabilities194M1.98B2.04B2.02B1.74B
Common Stock865M600K600K600K600K
Retained Earnings0(577.1M)(541.1M)(498.6M)(445.6M)
Accumulated OCI(271M)(324.9M)(309.1M)(292.8M)(285.6M)
Other Stockholders Equity00000
Minority Interest00000
Total Equity594M(891.4M)(821.7M)(738.3M)(650.6M)
Total Debt4.1M1.64B1.64B1.61B1.43B
Net Debt4.1M1.31B1.31B1.34B1.2B

Embecta Corp.

NASDAQ:EMBC

Intrinsic Alpha fair value

Locked

Current Price

$6.09

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.